Air Liquide ALIAD

What Air Liquide ALIAD does

Air Liquide ALIAD (legal name: AL INVESTISSEMENTS D'AVENIR ET DE DEMONSTRATION) is a wholly-owned subsidiary of Air Liquide S.A., established in 2013 and headquartered in Paris, France. ALIAD functions as the Group's dedicated vehicle for investments in future technologies and technology demonstrations, operating within Air Liquide's broader innovation network that includes more than 5,600 innovation-focused employees and 320 patent applications filed annually. Its mandate centers on deploying minority venture capital into deep-tech and decarbonization startups (e.g., a ~$1.875M participation in Ammobia's $7.5M seed round for low-cost ammonia technology in January 2026, and an investment in quantum-processor start-up Quobly in June 2026), as well as supporting demonstration projects such as the ACCSION carbon capture initiative with Aalborg Portland.

ALIAD sits inside L'AIR LIQUIDE S.A., a publicly traded company on Euronext Paris (ticker AI), founded in 1902 and led by Chairman Benoît Potier and CEO François Jackow. The parent Group generated €26.9bn in 2025 revenue and €3.5bn in net income, serving 4.3 million customers and patients across 59 countries through industrial gases (oxygen, nitrogen, argon, helium, hydrogen, CO2) and healthcare services. Core products include industrial gases and cryogenic hydrogen liquefaction, CO2 capture and storage, medical gases for approximately 20,000 hospitals and clinics, Air Liquide Healthcare's home healthcare for 2.3 million patients with chronic conditions, and Seppic specialty ingredients (€4.378bn revenue in 2025).

ALIAD does not generate standalone revenue reported in the input data; its economic role is option-value creation for Air Liquide Group, providing early exposure to technologies (clean ammonia, quantum, CCS, advanced semiconductors) that could become future core businesses. The Group's revenue model combines long-term industrial take-or-pay contracts, recurring subscription-like healthcare services for chronic disease patients, and direct specialty ingredients sales, supported by local-for-local production in 59 countries and a 80,000-strong supplier base. ALIAD is staffed at the Group level by an investment director (Greg Fleming) and reports into the parent company's governance structure.

Name

Air Liquide ALIAD

Legal name

L'AIR LIQUIDE S.A.

Website

https://airliquide.com

Company type

Public

Founded year

1902

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

ALIAD is the corporate venture and technology demonstration arm of Air Liquide, investing in and piloting future technologies such as low-carbon hydrogen, carbon capture, advanced ammonia, and quantum processors within Air Liquide's global industrial gas and healthcare platform spanning 59 countries.

Ownership category

akta.pro rank

Product category

Corporate Venture Capital and Industrial Technology Investment

NAICS

Industrial Gas Manufacturing (32512), Other Chemical Product and Preparation Manufacturing (3259)

akta.pro primary industry

Air Separation (Oxygen/Nitrogen/Argon) (IMAEACAA)

akta.pro secondary industry

AI/ML Engineering & Model Development Services (BPAEAHAF)

Keywords

• Venture capital investing
• Clean energy technology
• Carbon capture solutions
• Hydrogen production technology
• Industrial decarbonization investments

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Investment capital deployed (equity participations), Personnel, Operations, Technology or R&D

Revenue model

1. Industrial Gases Sales: Sale of industrial gases (oxygen, nitrogen, argon, helium, hydrogen, CO2) to industrial customers across multiple sectors including manufacturing, energy, food, electronics, and chemicals. Production occurs locally near customer facilities.
2. Healthcare Services: Home healthcare services for chronic disease patients including respiratory care, diabetes management, and perfusion therapies. Revenue from medical gases and associated services to hospitals and healthcare facilities.
3. Specialty Ingredients (Seppic): Through subsidiary Seppic, develops and provides innovative specialty ingredients (excipients and active ingredients) for cosmetics, pharmaceutical, nutrition and vaccine markets.
4. Technology and Equipment Services: Services include installation and maintenance of gas distribution systems, healthcare professional training, safety programs, and medical equipment provision.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

ALIAD is the dedicated corporate venture capital and future-technology demonstration investment arm of Air Liquide S.A., providing minority equity capital and co-development support to early-stage companies developing breakthrough technologies in clean energy, industrial decarbonization, and frontier manufacturing. Its activities include seed and early-stage equity participation alongside other strategic corporate venture investors, and demonstration-scale industrial project partnerships that pilot next-generation technologies (such as low-cost ammonia synthesis, quantum processor manufacturing, and large-scale CO2 capture from cement) for eventual integration into the Air Liquide Group's industrial gas, hydrogen, and energy transition portfolio.

Product overview

Air Liquide is a world leader in gases, technologies and services for industry and healthcare, operating with a platform-plus-modules architecture. The core offerings include industrial gases (Oxygen, Nitrogen, Helium, Argon, Hydrogen, CO2) and healthcare solutions. Within healthcare, three main product lines operate: Home Healthcare Services for chronic disease management (respiratory, diabetes, Parkinson's), Medical Gases and Associated Services for hospitals and clinics, and Seppic specialty ingredients for pharmaceutical and cosmetic markets. Additional offerings include Hydrogen Solutions for energy transition and CO2 Capture and Storage technologies for industrial decarbonization. The company serves over 4 million customers and patients across 59 countries with approximately 65,000 employees.

Differentiator

Problem solved

Functional benefit

Brands

• Seppic: Develops innovative specialty ingredients (excipients and active ingredients) for cosmetics, pharmaceutical, nutrition and vaccine markets.
• VitalAire
• Seppic

Products and services

• Ammobia Seed Investment (Low-Cost Ammonia Technology) Minority equity investment in Ammobia, a San Francisco-based startup developing a next-generation "Haber-Bosch 2.0" reactor for low-cost ammonia synthesis targeting fertilizer, maritime shipping, and power generation markets. The technology operates at lower pressure and 150°C lower temperature than conventional processes with the potential to reduce synthesis loop costs by up to half.
• Quobly Investment (Quantum Processor Manufacturing) Minority equity investment in Quobly, a start-up advancing quantum processor manufacturing technology, supporting Air Liquide's strategic interest in frontier semiconductor and quantum computing applications relevant to its electronics and specialty gas customers.
• ACCSION Industrial CO2 Capture Demonstration Project

Quantifiable outcome

• Air Liquide Healthcare cares for 2.3 million patients at home across 30+ countries
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• SillenocoreStrategic or Co-development Partner · 24 June 2026Air Liquide continued its long-term growth in Kazakhstan with a key investment to support Silleno's world-scale industrial plant.
• ArianeGroupcoreStrategic or Co-development Partner · 11 June 2026Air Liquide and ArianeGroup renewed their strategic industrial partnership with two major Ariane 6 contracts, supporting space launch capabilities.
• Aalborg PortlandcoreStrategic or Co-development Partner · 6 February 2026Air Liquide is collaborating with Aalborg Portland on the ACCSION project, a major CO2 capture project planned to be one of Europe's largest industrial CO2 capture facilities. The facility aims to capture up to 1.4 million tonnes of CO2 annually from cement production, with commissioning targeted for 2030.
• SK hynixcoreStrategic or Co-development PartnerAir Liquide announced a milestone investment in South Korea to support SK hynix's advanced AI memory chip project.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Linde plc: Linde is the world's largest industrial gases and engineering company, directly competing with Air Liquide across oxygen, nitrogen, argon, hydrogen, and medical gases globally, with overlapping healthcare and clean-energy strategies.
• Air Products and Chemicals: Air Products is a leading global industrial gases company with comparable scale in merchant and on-site gases, and an aggressive hydrogen/energy-transition roadmap that directly overlaps Air Liquide's strategy.
• Messer Group: Messer is a privately-held global industrial gases competitor with similar portfolio of oxygen, nitrogen, argon, hydrogen, and CO2, plus medical gases; it is the world's largest privately owned company in the space and a direct rival in Europe and the Americas.
• Nippon Sanso Holdings: Nippon Sanso (parent of Matheson Tri-Gas) is one of the four major industrial gas companies globally, directly competing in merchant and on-site gases, electronics gases, and increasingly in hydrogen, with comparable technology-driven positioning.
• Iwatani Corporation: Iwatani is Japan's leading industrial gas and hydrogen energy company with strong direct overlap with Air Liquide in liquid hydrogen, specialty gases, and energy-transition solutions across Asia.

Regional players

• SOL S.p.A. SOL Group is a European industrial and medical gas producer headquartered in Italy with comparable offerings in oxygen, nitrogen, argon, and home healthcare; primarily competing in Southern and Eastern Europe where Air Liquide also has a footprint.
• Yingde Gases Group: Yingde is one of China's largest independent industrial gas suppliers serving on-site and merchant customers; comparable to Air Liquide in product mix but focused almost exclusively on the Greater China market.

Others

• Chart Industries: Chart Industries designs and manufactures cryogenic equipment and process technology used across the industrial-gas supply chain, including hydrogen and CO2, making it an adjacent infrastructure provider to Air Liquide's gas and CCS operations.
• Croda International: Croda is a global specialty ingredients supplier serving personal care, pharma, and crop care — comparable to Air Liquide's Seppic subsidiary in the specialty chemistry value chain and overlapping customer bases in cosmetics and pharma excipients.
• AdaptHealth Corp: AdaptHealth is a US-focused home medical equipment and chronic-condition management provider, comparable to Air Liquide Healthcare's home-care business for sleep apnea, COPD, and diabetes across overlapping patient populations.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/AirLiquideCorp
• Facebookfacebook.com/AirLiquide
• LinkedInlinkedin.com/company/airliquide

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Air Liquide ALIAD